Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Mar;69(3):292-304.
doi: 10.1111/ijcp.12605. Epub 2015 Feb 16.

Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis

J M Amate  1 , T Lopez-Cuadrado, N Almendro, C Bouza, Z Saz-Parkinson, R Rivas-Ruiz, J Gonzalez-Canudas
Affiliations
Meta-Analysis

Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis

J M Amate et al. Int J Clin Pract. 2015 Mar.

Abstract

Objective: Our review analyses the studies that have specifically compared the association iDPP4/metformin with glimepiride/metformin, both in second line pharmacotherapy of type 2 diabetes mellitus (DM2).

Methods: Systematic literature review with a meta-analysis of clinical trials comparing glimepiride with any iDPP4, both used together with metformin as a second line treatment of DM2. The effectiveness variables used were as follows: %HbA1c variation, fasting plasma glucose variation, patients achieving the therapeutic objective of HbA1c <7%, treatment dropouts due to lack of effectiveness and rescue treatments needed. The safety variables included were as follows: weight variation at the end of treatment; presentation of any type of adverse event; presentation of serious adverse events; patients who experienced any type of hypoglycaemia; patients who experienced severe hypoglycaemia; treatments suspended due to adverse effects; and deaths for any reason.

Results: Four studies met the inclusion criteria. The group treated with glimepiride showed better results in all effectiveness variables. Regarding safety variables, the main differences observed were in the greater number of cases with hypoglycaemia in the group treated with glimepiride, and the serious adverse events or treatment discontinuations due to these which occurred in slightly over 2% more cases in this group compared to the iDPP4 group. The remaining adverse events, including mortality, did not show any differences between both groups. The variation in the weight difference between groups (2.1 kg) is not considered clinically relevant.

Conclusions: A greater effectiveness is seen in the glimepiride/metformin association, which should not be diminished by slight differences in adverse effects, with absence of severe hypoglycaemia in over 98% of patients under treatment. The association of glimepiride/metformin, both due to cost as well as effectiveness and safety, may be the preferential treatment for most DM2 patients, and it offers a potential advantage in refractory hyperglycemic populations, tolerant to treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bibliographic search diagram
Figure 2
Figure 2
Assessment of the methodological quality of studies
Figure 3
Figure 3
Meta‐analysis of HbA1c (%) reduction after treatment
Figure 4
Figure 4
Risk of dropout because of the lack of effectiveness
Figure 5
Figure 5
Risk of serious adverse effects
Figure 6
Figure 6
Risk of death for any season
See this image and copyright information in PMC

References

    1. Danaei G, Finucane MM, Lu Y et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country‐years and 2.7 million participants. Lancet 2011; 378(9785): 31–40. - PubMed
    1. International Diabetes Federation . Diabetes Atlas, 6th edn ISBN: 2‐930229‐85‐3: International Diabetes Federation, 2013.
    1. WHO . 10 facts about diabetes. http://www.whoint/features/factfiles/diabetes/facts/en/index7.html (accessed February 18, 2014).
    1. American Diabetes Association . Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36(4): 1033–46. - PMC - PubMed
    1. Breton MC, Guenette L, Amiche MA, Kayibanda JF, Gregoire JP, Moisan J. Burden of diabetes on the ability to work: a systematic review. Diabetes Care 2013; 36(3): 740–9. - PMC - PubMed

MeSH terms

LinkOut - more resources